Last reviewed · How we verify

Clofibrin (CLOFIBRIC ACID)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 20/100

Clofibrin (generic name: CLOFIBRIC ACID) is a clofibric acid drug. It is currently FDA-approved.

Clofibrin is a small molecule with the synonyms ACIDE CLOFIBRIQUE, ACIDO CLOFIBRICO, CLOFIBRIC ACID, and CLOFIBRIC ACID.

At a glance

Generic nameCLOFIBRIC ACID
Drug classclofibric acid
TargetLipoprotein lipase, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor alpha
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clofibrin

What is Clofibrin?

Clofibrin (CLOFIBRIC ACID) is a clofibric acid drug.

What is the generic name of Clofibrin?

CLOFIBRIC ACID is the generic (nonproprietary) name of Clofibrin.

What drug class is Clofibrin in?

Clofibrin belongs to the clofibric acid class. See all clofibric acid drugs at /class/clofibric-acid.

What development phase is Clofibrin in?

Clofibrin is FDA-approved (marketed).

What does Clofibrin target?

Clofibrin targets Lipoprotein lipase, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor alpha and is a clofibric acid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing